Tenax Therapeutics CEO Christopher Giordano acquires $20,087 in shares

Joana Goncalves, Chief Medical Officer at Oruka Therapeutics, sold 7,947 shares of the company's common stock on September 15, 2026, for about $734,144. The biotech firm's shares were trading at $92.20, up 518% over the past year, but analysts consider it overvalued. The sale followed the exercise of employee stock options and warrants.

Most of the shares were sold via a Rule 10b5-1 trading plan, with prices ranging from $91.10 to $94.22. Ms. Goncalves used part of the proceeds to cover tax obligations from restricted stock units, selling the remaining 947 shares at $95.71. Before selling, she bought 7,000 shares using options and warrants, which she exercised on the same day.

These options and warrants had prices between $6.84 and $7.80, valued at about $51,240. After the reported transactions, Ms. Goncalves directly owns 31,771 shares and also holds 193,563 employee stock options and 164,992 employee warrants. Oruka Therapeutics has a market capitalization of $6.35 billion, but it is still not profitable. Analysts predict a bullish outlook for the company, with price targets ranging from $117 to $200.